Immunophenotyping in adult acute myeloid leukemia: which prognostic value?

##plugins.themes.academic_pro.article.sidebar##

Published Sep 11, 2012
Download
pdf
Vol. 90 No. 8 (2012): Issue Aug 2012

##plugins.themes.academic_pro.article.main##

Naouel Ben Salah
Emna Gouider
Hajer Aounallah Skhiri
Wijdene El Borgi
Moenes Jouabli
Fatma Ben Lakhal
Ramzi Jeddi
Raouf Hafsia

Abstract

Bachground: Immunophenotyping is an essential step in the diagnosis of acute myeloid leukemia. Its prognostic value remains controversial with contradictory results.
Aim: To assess prognostic impact of the immunophenotyping in AML.
Methods: Our study is retrospective (October, 2005 - July, 2007) concerning 56 cases of AML (AML3 excluded) of the adult from 18 to 55 years old diagnosed and treated in Tunis Aziza Othmana Hospital. The immunophenotyping was performed by flow cytometry (Beckman Coulter EPICS XL MCL®). We studied clinical and biological characteristic, immunophenotypic expressions, and parameters of the response to the treatment: complete remission (CR), overall survival (OS), relapse free survival (RFS) and relapse in a delay of 1 year and 2 years. SPSS software was used to perform the statistical analysis
Results: The median age of the patients is of 37,7±11.8 years. Sexratio (M/F) is 1.33. Among individual antigenic expressions, only CD7 is associated to lower CR rates (p=0.044). We did not find any statistically significant association between immunophenotypic expressions and OS nor with relapse or RFS.
Conclusion: The impact of immunophenotyping in AML remains controversial because of contradictory results. The research of molecular changes would be an interesting alternative in our context.

##plugins.themes.academic_pro.article.details##

References

  1. Swirsky DM, Richards JJ. Laboratory diagnosis of acute myeloid leukemia. Best Pract Res Cl Haematol 2001; 14:1-17.
  2. Zuo Z, Chandra P, Wen YH, Koeppen H. Molecular diagnosis of acute myeloid leukemia. Diagn Histopathol 2009; 15:531-9.
  3. Latger -Cannard V, Jamain N, Lesesve JF, Buisine J. Immunophénotypage des leucémies aigues : utilisation du CD 45en troisième couleur pour améliorer la discrimination des cellules blastiques. Rev Fr Lab 2000 ; 319 : 37-43.
  4. Burnett AK, Goldstone AH, Stevens RM et al. Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet. 1998 ; 7;351(9104):700-8.
  5. Konoplev S, Bueso-Ramos CE. Advances in the pathologic diagnosis and biology of acute myeloid leukemia. Annals Diagn Pathol 2006; 10:39-65
  6. Valensi F. Classification des leucémies aiguës. Apports des propositions de l'Organisation mondiale de la santé. Encycl méd chir 2003, Hématologie ; 13-018-G-05.
  7. Casasnovas RO, Slimane FK, Garand R, et al. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome.Leukemia. 2003; 17:515-27.
  8. Chang H, Salma F, YI QL et al. Prognostic relevance of immunophenotyping of 379 patients with acute myeloid leukemia. Leuk Res 2004; 24:43-48.
  9. Geller RB, Zuhurak M, Hurwitz CA et al. Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem-cell glycoprotein CD34 (My10). Br J Haematol. 1990 ; 76 : 340-47. Abstract
  10. Legrand O, Perrot JY, Baudard M et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood 2000; 96: 870-7.
  11. Bradstock K, Matthews J, Benson E, Page F , Bishop J, and “the Australian Leukaemia Study Group”. Prognostic value of immunophenotyping in acute myeloid leukemia.Blood 1994;84: 1220-25.
  12. Repp R, Schaekel U, Helm G et al. Immunophenotyping is an independent factor for risk stratification in AML. Cytometry Part B (Clinical cytometry) 2003; 53 (B): 11-19.
  13. Mason KD, Juneja SK, Szer J. The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis? Blood Reviews 2006 ; 20 : 71-82.
  14. Stoppa AM, Vey N, RBouabdallah R et al. Pronostic et traitement des leucémies aiguës myéloblastiques. Encycl Méd Chir 2002, Hématologie ; 13-018-G-50.
  15. Solary E, Casanovas RO, Campos L et al. Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR--phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucémies (GEIL).Leukemia 1992; 6 : 393-99. Abstract.
  16. Kita K, Miwa H, Nakase K et al. Clinical importance of CD 7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia/Lymphoma. Blood 1993; 81: 399-407.
  17. Raspadori D, Damiani D, Michieli M et al. CD56 and PGP expression in acute myeloid leukemia: impact on clinical research outcome. Haematologica 2002 ; 87 : 1135-40.
  18. Pera G, Domingo A, Villamor N et al. Adverse prognostic impact of CD 36 and CD2 expression in adult de novo acute myeloid leukemia patients. Leuk. Res 2005; 29:1109-16.
  19. Kahl C, Florschutz A, Leuner S et al. Immunophenotypic analysis enables the correct prediction of t(8,21) in acute myeloid leukemia. Br J Haematol 1998; 102:444-8.
  20. Ball ED, Davis BR, Griffin JD et al. Prognostic value of lymphocyte surface markers in acute myeloid leukemia.Blood 1991; 77: 2242-50.
  21. Venditti A, Del Poeta G, Buccisano F et al. Progostic relevance of the expression of TdT and CD7 in 335 cases of acute myeloid leukemia. Leukemia 1998;12 1056-63.
  22. Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T. The role of multiparameter flow cytometry for disease monitoring in AML. Best Pract Res Clin Haematol 2010; 379-90.